No runway expansion at Mangaluru Airport for now

New Delhi, Jan 24: A nurse from Kerala employed at a hospital in Saudi Arabia has tested positive for the deadly novel coronavirus, Union minister of state for external affairs V Muraleedharan said on Thursday.

The minister confirmed that about 100 Indian nurses working in the Saudi Arabia hospital were tested following the threat of coronavirus and one of them was found infected by the deadly virus.

Taking to Twitter, MoS (MEA) Muraleedharan said, "About 100 Indian nurses mostly from Kerala working at Al-Hayat hospital have been tested and none except one nurse was found infected by Coronavirus. Affected nurse is being treated at Aseer National Hospital and is recovering well."

Earlier in the day, he had said that he was in touch with the Indian consulate in Jeddah to provide all possible support to the nurses quarantined at Al-Hayat hospital.

"Spoke to @CGIJeddah on Indian nurses quarantined at Al-Hayat Hospital, Khamis Mushait, Saudi Arabia due to Corona virus threat. They are in touch with hospital management and Saudi foreign Ministry. Have asked our Consulate to provide all possible support", he had tweeted.

Kerala chief minister Pinarayi Vijayan on Thursday wrote to the external affairs ministry seeking intervention in Corona outbreak among Kerala nurses in Saudi Arabia

"Corona outbreak among nurses in Azir Aba Al Hayat hospital in Saudi Arabia should be considered serious and necessary steps must be taken", he had said through the letter.

The chief minister had also requested MEA to communicate with Saudi Arabia to ensure proper treatment and protection for the patients.

Mangaluru, Jan 14: Mangaluru city police commissionerate his notified traffic diversions on NH 73 in view of massive protest at Adyra Kannur in the city against CAA, NPR and NRC on January 15. It also has issued guidelines for the public, protesters and organisers of the protest.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.